Last reviewed · How we verify
NCT04989101: NigCOV3
Nigelle 5 in Prevention of Influanza
NA trial testing Nigella in COVID-19 Acute Respiratory Distress Syndrome in 500 participants. Completed in 31 August 2021.
31 July 2021
Quick facts
| Lead sponsor | Hôpital Universitaire Sahloul |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 500 |
| Start date | 5 June 2021 |
| Primary completion | 31 July 2021 |
| Estimated completion | 31 August 2021 |
| Sites | 1 location across Tunisia |
Drugs / interventions tested
- Nigella — full drug profile →
Conditions studied
- COVID-19 Acute Respiratory Distress Syndrome — all drugs for COVID-19 Acute Respiratory Distress Syndrome →
Sponsor
Hôpital Universitaire Sahloul — full company profile →
Who can join
40 and older, any sex, with COVID-19 Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will be carried out by more than 30 liberal Tunisian doctors, who will submit according to the inclusion / exclusion criteria of people who will receive (free of charge) a capsule of the Nig5 product sublingually, each day. Against a control group which will be followed with the same protocol as the first but which will not receive the product. Randomization (even days: nigella group, odd days: control group)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
<i>Nigella sativa</i> L. and COVID-19: A Glance at The Anti-COVID-19 Chemical Constituents, Clinical Trials, Inventions, and Patent Literature.
Imran M, Khan SA, Abida, Alshammari MK, et al · · 2022 · cited 10× · PMID 35566101 · DOI 10.3390/molecules27092750
Verify or expand the search:
- PubMed search for NCT04989101
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nigella
Trials testing the same drug.
- NCT04914767 — Nigella 5 in the Treatment of SARS COV2 (COVID-19) · Phase 1 · completed
Other recruiting trials for COVID-19 Acute Respiratory Distress Syndrome
Currently open trials in the same condition.
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT04964115 — Post Acute Sequelae of COVID-19 · active not recruiting
- NCT05164744 — Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors · recruiting
- NCT04896853 — Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® · Phase 1 · active not recruiting
Other Hôpital Universitaire Sahloul trials
Trials by the same sponsor.
- NCT07329881 — Artificial Intelligence Algorithm for the Interpretation of Traumatic Bone Radiographs · active not recruiting
- NCT07147699 — Evaluation of the Effectiveness of the CardioStory Device in Distinguishing Heart Failure From Other Causes in Patients · not yet recruiting
- NCT07089277 — External Validation of the Glasgow-Blatchford Bleeding Score in a Tunisian Population · recruiting
- NCT06953154 — Monocyte Distribution Width (MDW): An Early Marker of Sepsis in Patients With Comorbidities · completed
- NCT05646433 — Validation of a New Score for UGI Bleeding in the ED: the Study of the TU-GIB Score · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04989101 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hôpital Universitaire Sahloul
- Last refreshed: 24 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04989101.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing